Next Phase Newsletter

A global investor, headquartered in Western Europe with no geographical restrictions, and is actively seeking new investment opportunities. The firm is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic diseases. The firm makes selective investments in newly founded or early-stage companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. Typically, the firm invests in incorporated companies from seed stage onwards, and it can invest $25-30M over the lifetime of the companies. The firm’s current fund has a core strategy to invest in early stage companies, but the funds will also be used to invest in late stage financings, cross-over financings, IPO’s, and listed stock. These companies can either be portfolio companies or external companies. 
 
In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies and therapeutics targeting genetic diseases, and is open to all types of therapeutic modalities and all indications relevant to those spaces, including platform technologies. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Projects will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa). 
 
At its core, the firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of its portfolio companies. To this end, DROIA has several experts in oncology and genetic diseases, intellectual property, and drug development on the investment team which are available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A healthcare technology-focused venture capital firm invests primarily in pre-Seed, Seed, Bridge, and Series A financing rounds and is currently investing from their second fund. Typical investment size ranges from $100-250k, with potential for follow on. The firm welcomes global opportunities, but will invest primarily in the “Americas” (North or South America). 
 
The firm is particularly interested in the areas of mental health, longevity, and chronic conditions, and technologies that can promote prevention, better access, and better quality of care. With their current fund, the firm seeks to invest into more biotech companies, and will consider all modalities. The firm will also continue to invest in medical devices, diagnostics, and digital health companies that address their key focus areas, with an open interest in various types of technologies within these main sectors. In terms of stage of development, the firm is open to pre-clinical, pre-revenue generating companies with demonstrated proof of concept. 
 
The firm does not have specific company or management team requirements. The firm can act as either a lead or co-investor, will typically seek board representation when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture capital firm invests globally in technologies with potential to impact mortality rates at scale by improving healthcare quality and outcomes to support the parent company’s initiatives. The firm’s fund prioritizes technologies that address acute, time-critical conditions and makes investments internationally. The firm will invest up to $5M USD for their first check with capital reserved to follow on. The firm is actively deploying capital. 
 
The firm invests solely in medical devices, diagnostics, and digital health. The fund does not invest in therapeutics, biotech, pharma, and CROs. The fund looks at acute, time-critical areas of healthcare and is interested in solutions that support prevention, earlier identification and intervention, and improved therapeutics for these conditions. Key areas of focus include, but are not limited to cardiovascular care, sepsis, stroke, trauma and surgery, maternal and neonatal care, emergency medicine, and healthcare education & training. 
 
The firm can act both as a lead and co-investor. The firm needs to see committed and full-time teams with demonstrated product market fit. The fund invests in pre- and post- FDA approval companies, but companies should have an MVP and licensed IP where relevant. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A life science venture capital firm with extensive global access and unique cross-border expertise. The firm discovers, incubates and grows next-generation life science companies in early and growth stage. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in USA and China. 
 
The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage. 
 
The firm has no specific requirement for the company & management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.